Fred Middleton

Fred A. Middleton currently works at Altor BioScience Corp., as Vice Chairman & Chief Business Officer, Sanderling Management CO LLC, as Managing Director from 1988, Cylene Pharmaceuticals, Inc., as Director, Actimis Pharmaceuticals, Inc., as Director from 2008, Middleton, McNeil & Mills Associates V LLC, as Managing Director, TheraVida, Inc., as Director, Lineagen, Inc., as Director from 2008, CalciMedica, Inc., as Independent Director from 2020, Asteres, Inc., as Director, Mesa Verde Ventures LLC, as Managing Director, and MIT Corp.
(United States), as Member from 2007.
Mr. Middleton also formerly worked at Genteric, Inc., as Chairman from 1978 to 2008, Regeneron Pharmaceuticals, Inc., as Chief Financial Officer & Director from 1988 to 2001, Favrille, Inc., as Director from 2002 to 2009, CardioNet LLC, as Independent Director in 2011, Stereotaxis, Inc., as Independent Director from 2012 to 2018, Axikin Pharmaceuticals, Inc., as Director, Pacira Biosciences, Inc., as Director in 2013, Endocyte, Inc., as Independent Director from 2011 to 2018, CoMentis, Inc., as Director, HCW Biologics Inc., as Director, ViaCyte, Inc., as Director from 2020 to 2022, Chimerix, Inc., as Independent Director from 2018 to 2025, Genentech, Inc., as Chief Financial Officer & VP-Administration from 1978 to 1984, The Chase Manhattan Bank NA, as Vice President-Planning & Development in 1984, Morgan Stanley & Co. LLC, as Managing General Partner in 1986, McKinsey & Co., Inc., as Consultant, and Genentech Development Corp., as President.
Mr. Middleton received his undergraduate degree in 1971 from Massachusetts Institute of Technology and Masters Business Admin degree in 1973 from Harvard Business School.